Spero therapeutics announces first patient dosed with spr720 in phase 2a clinical trial in patients with nontuberculous mycobacterial pulmonary disease

Cambridge, mass., dec. 10, 2020 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (mdr) bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease (ntm-pd) in its dose-ranging phase 2a clinical trial of spr720, spero's oral antimicrobial agent in development for the treatment of ntm-pd.
SPRO Ratings Summary
SPRO Quant Ranking